NRC Health (NASDAQ: NRC) hits $152M TRCV with 13% YoY growth

Rhea-AI Filing Summary

National Research Corporation, doing business as NRC Health, reported that its Total Recurring Contract Value (TRCV) has surpassed $152 million as of March 4, 2026, an all‑time high for the company.

The company said TRCV, which reflects projected revenue over the next 12 months from renewable contracts, increased 6% since the end of 2025 and 13% year‑over‑year. Management framed this growth as evidence of strong, long‑term relationships with health system partners, but emphasized that this update does not represent complete financial results for the quarter ended March 31, 2026.

Positive

• Total Recurring Contract Value reaches an all-time high above $152 million as of March 4, 2026, rising 6% since year-end 2025 and 13% year-over-year, highlighting growth in projected 12-month revenue from renewable contracts.

Negative

• None.

Insights

Healthcare SaaS & Recurring Revenue Analyst

All-time high recurring contract value signals solid demand momentum.

NRC Health reports Total Recurring Contract Value above $152 million as of March 4, 2026. TRCV, defined as projected 12‑month revenue from renewable contracts, is up 6% from the end of 2025 and 13% year‑over‑year, indicating expanding contracted revenue.

This metric highlights the scale and growth of NRC Health’s renewable business rather than full quarterly results. Management links the increase to deeper relationships with health systems and the perceived importance of its platform in customer growth and operations.

The company notes that this milestone does not reflect complete results for the quarter ended March 31, 2026, so investors will need subsequent filings to understand margins, cash flow, and earnings alongside this recurring revenue trajectory.

false 0000070487 0000070487 2026-03-04 2026-03-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

March 4, 2026

National Research Corporation

(Exact name of registrant as specified in its charter)

Delaware	001-35929	47-0634000
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1245 Q Street, Lincoln, Nebraska	68508
(Address of principal executive offices)	(Zip Code)

(402) 475-2525

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
$.001 Par Value Common Stock	NRC	The NASDAQ Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01	Regulation FD Disclosure.
	On March 4, 2026, National Research Corporation, a Delaware corporation (the "Company"), issued a press release announcing that it has surpassed $152 million in Total Recurring Contract Value (TRCV) as of March 4, 2026, representing an all-time high in the metric for the Company. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated by reference herein.
Item 9.01	Financial Statements and Exhibits.
	(d)	Exhibits.
	EXHIBIT NUMBER	EXHIBIT DESCRIPTION
	99.1	National Research Corporation press release providing business update.
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document).
	The information contained in Items 7.01 and 9.01 of this report and the exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
	The information in Items 7.01 and 9.01 of this report and the exhibits hereto may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements are made based on the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results or events may differ from those anticipated by forward-looking statements. Please refer to the paragraph at the end of the attached press release and various disclosures by the Company in its press releases, stockholder reports, and filings with the Securities and Exchange Commission for information concerning risks, uncertainties, and other factors that may affect future results.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NATIONAL RESEARCH CORPORATION
	(Registrant)
Date: March 4, 2026	By:	/s/ Shane Harrison
		Shane Harrison
		Executive Vice President and Chief Financial Officer

Exhibit 99.1

1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061
nrchealth.com

NRC HEALTH PROVIDES BUSINESS UPDATE

TRCV surpasses $152 million, increasing 6% from the end of 2025 and 13% year-over-year

LINCOLN, Nebraska, March 4, 2026 — National Research Corporation, dba NRC Health, (NASDAQ: NRC), a leader in healthcare experience improvement solutions, today announced that it has surpassed $152 million in Total Recurring Contract Value (TRCV) as of March 4, 2026, representing an all-time high in the metric for NRC Health.

TRCV represents the amount of revenue projected to be recognized over the next 12 months from renewable contracts and is calculated consistent with the definition previously disclosed in the company’s periodic reports filed with the Securities and Exchange Commission.

“This TRCV milestone reflects the confidence our health system partners place in NRC Health and the continued expansion of our long‑term relationships,” said Trent Green, Chief Executive Officer of NRC Health. “We believe our platform, which connects the voice of the consumer to decision‑making across the healthcare journey, is increasingly critical to our customers’ growth and operational strategies.”

The TRCV milestone announced today does not reflect the company’s complete financial results for the quarter ended March 31, 2026.

About NRC Health

For more than 40 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know the patients, families, consumers, employees, and communities they serve on a human level. Guided by its uniquely empathic heritage, human-centered approach, unmatched national market research, and emphasis on consumer preferences, NRC Health is transforming the healthcare experience, creating strong outcomes across the healthcare journey. For more information, email info@nrchealth.com, or visit www.nrchealth.com.

Forward-Looking Statements

This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as “believes,” “expect,” “focus,” “potential,” “will,” derivations thereof, and similar terms and phrases. In this press release, the statements related to future dividends are forward-looking statements. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2024, and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.

Media Contact

marketing@nrchealth.com

Investor Contact

ir@nrchealth.com

© NRC Health

FAQ

What business update did National Research Corporation (NRC) announce on March 4, 2026?

National Research Corporation announced that Total Recurring Contract Value exceeded $152 million as of March 4, 2026. This marks an all-time high for NRC Health and reflects projected revenue over the next 12 months from renewable contracts with healthcare clients.

How fast is NRC (National Research Corporation) growing its Total Recurring Contract Value?

NRC reported that Total Recurring Contract Value increased 6% since the end of 2025 and 13% year-over-year. This growth in projected 12‑month revenue from renewable contracts suggests expanding long-term relationships with health system partners using NRC Health’s experience improvement solutions.

What does Total Recurring Contract Value (TRCV) mean for NRC shareholders?

Total Recurring Contract Value represents projected revenue over the next 12 months from renewable contracts. For NRC shareholders, TRCV above $152 million indicates the scale and growth of NRC Health’s contracted, recurring business, though it is not the same as reported quarterly revenue or earnings.

Does NRC’s $152 million TRCV update include full Q1 2026 financial results?

No, NRC stated that the $152 million TRCV milestone does not reflect complete financial results for the quarter ended March 31, 2026. Full revenue, profit, and cash flow details will come from future periodic filings and financial disclosures covering that quarter.

How does NRC Health describe the reason behind its TRCV growth?

NRC Health’s CEO said the TRCV milestone reflects health system partners’ confidence and continued expansion of long-term relationships. Management believes its platform, connecting consumer voices to decisions across the healthcare journey, is increasingly important to customers’ growth and operational strategies.

Are there forward-looking statements in NRC’s March 4, 2026 business update?

Yes, NRC indicated the press release contains forward-looking statements, including those related to future dividends. These statements rely on management’s current expectations and are subject to risks and uncertainties described in NRC’s Annual Report on Form 10-K and other SEC filings.

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 7.9 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 11.2 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.3 KB